�鶹Ů��

Silicon Valley has audacious plans for shaking up the way we diagnose — and cure — disease. But the life sciences are far more challenging than the tech titans of this world might realize: There are countless regulatory hurdles, health care delivery obstacles, and — most of all — the challenge of untangling the extraordinarily complex biology of the human body. Still, giants like Apple, Google, IBM, Intel, and Microsoft are charging ahead. (Keshavaan, 4/13)

The controversial laboratory tool known as CRISPR may have found a whole new world to conquer. Already the favored method of editing genes, CRISPR could soon become a low-cost diagnostic tool that could be used practically anywhere to determine if someone has an infectious disease such as Zika or dengue. (Achenbach, 4/13)

For years, health experts have bemoaned the rise of childhood obesity in the United States. About 17% of kids and teens in the U.S. are now considered obese, a figure that has more than tripled since the 1970s, according to data from the Centers for Disease Control and Prevention. A report in this week’s edition of the New England Journal of Medicine lays out one of the consequences of all this excess weight: a corresponding increase in childhood cases of type 2 diabetes. (Kaplan, 4/14)

One of the nation’s largest homeopathy companies announced Thursday that it was recalling all of its infant teething tablets at the request of US regulators, following reports that the tablets had caused seizures and other severe complications in hundreds of infants. The company, Standard Homeopathic, said it was recalling the tablets at the request of the Food and Drug Administration, which had concluded that they contained inconsistent amounts of belladonna, an herb known colloquially as “deadly nightshade.” (4/13)